Back to Authors

Litzow, Mark R.

https://orcid.org/0000-0002-9816-6302

A5085360755 | I1330342723

Mayo Clinic

Citations 731

Differential Impact on Survival in Myeloid Neoplasm Patients with U2AF1 Mutations

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9602-9603

10.1182/blood-2022-167405

TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9798-9799

10.1182/blood-2022-165859

Venetoclax Plus Hypomethylating Agent (HMA) Based Induction for Treatment-Naive Older/Unfit Patients with FLT3-Mutated Acute Myeloid Leukemia (AML)

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9019-9020

10.1182/blood-2022-168303

Outcome of Patients with Acute Myeloid Leukemia Following Failure of Front-Line Venetoclax Plus Hypomethylating Agent Therapy

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1286-1287

10.1182/blood-2022-165491

A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2-Mutant AML Patients: 3-Year Follow-up

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 2016-2019

10.1182/blood-2022-166850

Characteristics and Prognostic Effects of DNMT3A Co-Mutations

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 745-747

10.1182/blood-2022-162526

Younger Matched Unrelated Donors Confer a Decreased Relapse Risk As Compared to Older Sibling Donors for Adult B-Cell ALL Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10540-10541

10.1182/blood-2022-163517

DNA Polymerase Theta Protects Leukemia Cells from Metabolic-Induced DNA Damage

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 2972-2974

10.1182/blood-2022-156458

Response Rates to Venetoclax Based Therapies in Chronic Phase and Blast Transformed Chronic Myelomonocytic Leukemia

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 12238-12240

10.1182/blood-2022-165470

Leukemic Transformation of Myeloproliferative Neoplasms in the Post-Ruxolitinib Era: Analysis of 103 Consecutive Cases Diagnosed 2011-2021

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9735-9736

10.1182/blood-2022-163450